Extended drug regimen may shield transplant patients from deadly immune attack

NCT ID NCT04380740

Recruiting now Disease control Sponsor: Boston Children's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving more doses of the drug abatacept over a longer period can better prevent graft-versus-host disease (GVHD), a serious complication where donor immune cells attack the patient's body. About 160 people receiving stem cell transplants from partially matched donors will be randomly assigned to either a standard short course or an extended course of abatacept, alongside usual medications. The goal is to see if the extended regimen improves survival without severe GVHD or relapse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm graft versus host disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT VS HOST DISEASE

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
ACTIVE_NOT_RECRUITING

Boston, Massachusetts, 02215, United States
Boston Children's Hospital
RECRUITING

Boston, Massachusetts, 02115, United States
Children's Healthcare of Atlanta
RECRUITING

Atlanta, Georgia, 30329, United States
Children's Hospital of Philadelphia
WITHDRAWN

Philadelphia, Pennsylvania, 19104, United States
Cincinnati Children's Hospital
ACTIVE_NOT_RECRUITING

Cincinnati, Ohio, 45229, United States
City Of Hope National Medical Center
ACTIVE_NOT_RECRUITING

Duarte, California, 91010, United States
Dana-Farber Cancer Institute
ACTIVE_NOT_RECRUITING

Boston, Massachusetts, 02215, United States
Emory University/Winship Cancer Center
ACTIVE_NOT_RECRUITING

Atlanta, Georgia, 30322, United States
Massachusetts General Hospital
ACTIVE_NOT_RECRUITING

Boston, Massachusetts, 02114, United States
Moffitt Cancer Center
ACTIVE_NOT_RECRUITING

Tampa, Florida, 33612, United States
Oregon Health and Sciences University
ACTIVE_NOT_RECRUITING

Portland, Oregon, 97239, United States
University of Chicago
RECRUITING

Chicago, Illinois, 60637, United States
University of Michigan
ACTIVE_NOT_RECRUITING

Ann Arbor, Michigan, 48109, United States
University of Rochester
RECRUITING

Rochester, New York, 14642, United States
Washington University St. Louis
WITHDRAWN

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.